

본태성 고혈압 환자에 대한 이베사탄(Irbesartan)의 유효성 및 안전성

엄 철¹ · 신준한¹ · 김한수¹ · 탁승제¹ · 고종훈¹ · 최병일¹
홍의수² · 서정기² · 권 준² · 박금수² · 이우형²

The Efficacy and Safety of Irbesartan in Treating Essential Hypertension

Cheol Eom, MD¹, Joon-Han Shin, MD¹, Han-Soo Kim, MD¹, Seung-Jae Tahk, MD¹,
Jong-Hoon Koh, MD¹, Byung-il William Choi, MD¹, Eui-Soo Hong, MD², Jeong-Kee Seo, MD²,
Jun Kwan, MD², Keum-Soo Park, MD² and Woo-Hyung Lee, MD¹

¹Department of Cardiology, College of Medicine, Ajou University, Suwon, ²Department of Cardiology,
College of Medicine, Inha University, Incheon, Korea

ABSTRACT

Background : Irbesartan, an orally active antihypertensive agent, effectively reduce blood pressure by directly blocking angiotensin receptors without any significant adverse effects. The purpose of this study is to evaluate the efficacy and safety of irbesartan in patients with mild to moderate hypertension. **Methods :** This study enrolled 83 patients who had diastolic pressure above 95 mmHg and below 110 mmHg on two measurements. Sixty eight patients were administered 150mg of irbesartan, an angiotensin II receptor blocker, daily for four weeks as an initial dosage. If the sitting diastolic pressure was equal to or greater than 90 mmHg after a 4 week treatment period, the dosage was doubled until the end of 8 weeks. Baseline pressures, antihypertensive effect, side effects, laboratory findings were compared before and after treatment. **Results :** Forty two patients out of 53 patients having completed this study showed decreased blood pressure equal to or more than 5 mmHg of the sitting diastolic pressure (response rate = 79%). Twenty one patients out of 53 patients showed normalized blood pressure below 90 mmHg of the sitting diastolic pressure (normalization rate = 40%). The extent of decrease in diastolic and systolic blood pressure after eight week treatment was an average 11.7 ± 10.1 mmHg and 16.3 ± 18.9 mmHg, respectively ($p < 0.05$). Nineteen ontoward side effects was observed in 17 patients out of 68 patients with medication (frequency of ontoward effects = 25%). Only one case with headache was considered to be related to the medication. Abnormal laboratory findings were observed in eight patients, and only one case with elevation of bilirubin and ALT levels was considered to be related to the medication. **Conclusion :** In conclusion, irbesartan is a safe and effective antihypertensive drug in patients with mild to moderate hypertension with tolerable side effects. (**Korean Circulation J 2000; 30(3):318-325**)

KEY WORDS : Irbesartan · Hypertension.

: 1999 6 28
: 2000 2 17
: , 442 - 721
: (0331) 219 - 5712 · : (0331) 219 - 5708

5

서 론

Renin - angiotensin - system(RAS) , otensin , renin ACE aldosteron
 .⁶⁾ irbesartan ACE
 angiotensin 가 .⁷⁾
 renin 가 가 renin angio - irbesartan 8
 tensinogen angiotensin ,
 angiotensin - converting - enzyme(ACE)
 angiotensin . angiotensin
 aldosterone 가 Na
 .¹⁾ RAS 1998 6
 ACE RAS ACE 1 1998 9 30
 angiotensin 18 2
 가 95 mmHg 110 mmHg
 .²⁾ captopril 1970
 ACE ACE 6
 1 (coronary artery bypass gr -
 .³⁾ ACE bradykin - aft)
 in, substance P peptide , ,
 , 가 ,
 .⁴⁾ ACE 200 mmHg , ,
 , an -
 ACE RAS ,
 , 12
 angiotensin 가 , , ,
 . angiotensin angiotensin , ,
 angiotensin 가
 ACE , ,
 ACE 가 , 가
 . 1993 .
 angiotensin
 losartan irbesartan, cande - 약물 투여 방법
 sartan, eprosartan, valsartan .⁵⁾ screening wash - out , pl -
 irbesartan AT1 가 acebo , wash - out
 angiotensin
 . irbesartan angi - 1

대상 및 방법

대 상

placebo placebo
 8 12 1 1 1 2
 (Fig. 1).
 placebo
 wash - out
 placebo
 95 110 mmHg
 wash - out
 8 irbesartan 1 1 1 (150 mg)
 8 12 4
 90 mmHg
 , 90 mmHg 1 1 2 (300 mmHg)
 4
 (, , ACE)

각종 검사
 screening 가
 X
 hemoglobin,
 hematocrit, RBC, WBC platelet count, differen -
 tial count , alanine tr -
 ansaminase(ALT), aspartate aminotransferase(AST),
 alkaline phosphatase, total protein, albumin, total
 bilirubin, BUN, glucose, creatinine, uric acid, elec -
 trolytes(Na, K, Cl, calium, phosphorus), total chol -
 esterol , protein, glucose,




Fig. 1. The time schedule of clinical trial of irbesartan.

cast(RBC, WBC) screening , 2 8
 .
 평가 방법
 가 placebo
 2
 2
 10 mmHg
 5 mmHg
 10 mmHg
 5 mmHg 가
 5 mmHg 가
 4
 90 mmHg
 .
 가
 . 8

가 side effect profile
 side effect profile 가
 2
 , X 8
 가
 자료 분석
 , ,
 paired t - test ANOVA
 .
 p 0.05
 .
 결 과

대상 환자의 임상적 특징
 83 sc -
 reening wash out 4 , placebo
 11 , 가 68
 . 68 8
 가 57 , 11 .
 가




Fig. 2. The algorithm of clinical trial of irbesartan.

가 1 , 가
 가 5 , 2 ,
 가 2
 , follow - up 가 5 15 .
 11
 가 가 2
 , 3 , follow - up 가 4 ,
 가 2
 (Fig. 2). 4 65
 35 (54%) 가 1 300 mg .
 68
 2 66
 (Table 1). 28 (42%), 가 38
 (58%) . 20 가 1 (2%), 30 가 5
 (8 %), 40 가 10 (15%), 50 가 36 (55%),
 60 가 12 (18%), 70 가 2 (2%) 53.4
 ± 9.4 . 1 가
 1 9 , 11 3
 4.0 ± 5.0 . 가 30
 (46%), 36 (54%) . 24 (36%)
 가 , ,
 가 . 45 (68%)
 screening
 11 (17%), 5
 (8%), 2가 가 9 (14%),
 가 18 (27%) . 46% 1 53
 8 3

Table 1. Baseline clinical characteristics (n = 66)

	Umber of cases
Sex male	28 (42%)
female	38 (58%)
Mean age (yr-old)	53.4 \pm 9.4
Mean duration of hypertension (yr)	4.0 \pm 5.0
Body weight (kg)	66.4 \pm 11.3
Family history of hypertension	30 (46%)
Presence of other medical history	24 (36%)
Previous pharmacological treatment	45 (68%)




Fig. 3. Response rate and Normalization rate of irbesartan.

유효성과 안전성

83 8
 57 3
 46% 1 53

1 가 68

가

8

5 mmHg 42

79%

90 mmHg 21

40% (Fig. 3).

104.0 ± 5.1

mmHg 8 92.2 ± 10.6 mmHg

11.7 ± 10.1 mmHg (p < 0.05).

11%) 가 2 4

96.2 ± 8.3 mmHg 91.2 ± 9.5 mmHg

7.0 ± 6.3 mmHg

12.8 ± 8.2 mmHg 가

(p < 0.05).

156.0 ± 15.2 mmHg 2, 4 8

141.2 ± 14.3 mmHg, 136.7 ± 15.6 mmHg,

138.5 ± 17.7 mmHg

15.0 ± 11.4 mmHg, 19.6 ± 13.7 mmHg 16.3

± 18.9 mmHg (p < 0.05).

2

, 4 8

. 4 8

(Fig. 4).

(p = NS).

8

26 27 가

104.0 ± 5.4 mmHg

8 91.2 ± 9.6 mmHg 12.8 ± 8.4 mmHg 가

103.9 ± 4.9 mmHg 8

93.2 ± 11.5 mmHg 10.7 ± 11.5 mmHg

가 .




Fig. 4. Reduction of the blood pressure during irbesartan trial. *p < 0.05 compared to baseline.

Table 2. The frequency of side effect profile (n = 68)

Side effect	Number of cases
Headache	4 (6%)
Fatigue	2 (3%)
Abdominal pain	2 (3%)
URI	2 (3%)
Musculoskeletal pain	1 (2%)
Weight loss	1 (2%)
Conjunctival injection	1 (2%)
Thirst	1 (2%)
Enteritis	1 (2%)
Chest pain	1 (2%)
Dizziness	1 (2%)
Dry cough	1 (2%)
General weakness	1 (2%)
Total	19 (25%)

153.1 ± 14.2 mmHg 8 134.7

± 16.7 mmHg 17.5 ± 16.8 mmHg 가

, 158.1 ± 15.8 mmHg 8

142.3 ± 18.2 mmHg 15.1 ± 19.4 mmHg 가

(p = NS).

Side effect profile

68 17

19 side effect 가 side effect

25% (Table 2).

가 가 4

Table 3. The abnormal laboratory test (n = 68)

The kinds of abnormal laboratory test	Number of cases
Hematology	Decreased platelet count 1 (2%)
	Increased WBC ¹ 2 (3%)
Serum chemistry	Increased ALP ² 1 (2%)
	Increased AST ³ , ALT ⁴ 1 (2%)
	Increased bilirubin, ALT 1 (2%)
Urinalysis	Increased urine RBC ⁵ 1 (2%)
	Increased urine blood 1 (2%)
Total	8 (12%)

1 : WBC = white blood cell
 2 : ALP = alkaline phosphatase
 3 : AST = aspartate aminotransferase
 4 : ALT = alanine transaminase
 5 : RBC = red blood cell

(6%) . 1
 가 가
 가 , 3 가
 ACE 가
 1
 ACE
 가 가
 , , 3 가
 가
 가
 2 8 가
 hematocrit al-
 bumin . hematocrit 41.0±4.0%,
 2 41.5±4.1%(p<0.05), 8 40.7±3.8%(p<

0.05) , albumin 가 4.64±0.27
 g/dL, 2 4.57±0.28g/dL(p<0.05), 8 4.52
 ±0.3g/dL(p<0.05) 가
 가
 .
 8 가
 neutrophil, calcium
 potassium . Neutrophil 가 51.3±8.7%,
 8 53.8±9.5%(p<0.05) 가
 , calcium 가 9.4±0.5 mg/dL, 8
 9.3±0.4 mg/dL(p<0.05)
 . potassium 가 4.2±0.3 mEq/L
 (mMol/L), 8 4.4±0.4 mEq/L(mMol/L)(p<0.05)
 가
 .
 8
 .
 고 안
 irbesartan 8
 5 mmHg
 , 79% ,
 90 mmHg
 21 40% .
 irbesartan
 .
 8-11)
 95 110 mmHg
 irbesartan 8 12
 9.7 12.3 mmHg,
 12.1 16.4 mmHg
 .
 40%
 50% .
 90 mmHg
 90 mmHg
 가 9 ,

cut - off va - 24 18 mmHg, 14 mmHg
lue 90 mmHg 30 .⁹⁾ enalapril 10
(57%) mg 40 mg
가 angiotensin 12 irbesartan 75 mg
가 an - 300 mg 12 irbesar -
giotensin tan
가 18 mmHg 13 mmHg가 enalapril
angiotensin 18 mmHg
, Kessler - Taub 14 mmHg가
10) .¹⁶⁾
mg irbesartan 300 mg losartan 100 olol, enalapril irbesartan aten -
mg losartan irbesartan side effect .⁹⁾¹⁶⁾
가 - 8.7 mmHg - 11.7 25% 가
mmHg , 1
Oparil ⁸⁾ bilirubin ALT 1
irbesartan losartan 1 (2%)
- 10.2 mmHg - 7.9 mmHg
irbesartan 가 hematocrit, albu -
가 min, neutrophil, calcium potassium
losartan
Belz ¹²⁾ Mazzolai ¹³⁾ in vitro ,
radioreceptor assay irbesartan losartan 가 가
가
losartan
가 losartan ¹⁴⁾¹⁵⁾ ACE
90 mmHg
losartan 50 mg(100 mg) 12
Kim ¹⁴⁾ irbesartan
100.7 ± 9.4 mmHg 85.9 ±
9.1 mmHg , Park ¹⁵⁾ irbesartan
9.4 ± 2.7 mmHg 1 1 150 300 mg
at -
enolol(beta - blocker),⁹⁾ enalapril(ACE inhibitor)¹⁶⁾ 요 약
irbesartan
irbesartan 75 mg 연구대상 :
300 mg 24 Irbesartan AT1
19 mmHg, 15
mmHg가 atenolol 50 mg 100 mg angiotensin

가

방법 :
2
mmHg 110 mmHg
83 angiotensin
besartan 1 150 mg
mg 90 mmHg 300
4 8
, side effect profile,

결과 :
83 가가 가 53
5 mmHg
42
79% , 90 mmHg
21
40% 8
11.7 ± 10.1 mmHg(11%)
(p<0.05).
16.3 ± 18.9 mmHg
(p<0.05).
1 68 17
19 side effect가
25 % 1
8
bilirubin ALT
1 가 가
가

결론 :
irbesartan

중심 단어 : Irbesartan.

REFERENCES

1) Ferrario CM. *The Renin-Angiotensin System: Importance in Physiology and Pathology. J Cardiovasc Pharmacol*

1990;15 (suppl.):S1-S5.

2) Kang PM, Landau AJ, Eberhardt RT, Frishman WH. *Angiotensin receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am Heart J* 1994; 127:1388-401.

3) Brogden RN, Todd PA, Sorkin EM. *Captopril: An update of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs* 1998;36:540-600.

4) Lacourciere Y, Brunner H, Irwin R, Kalberg BE, Ramsay LE, et al. *Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens* 1994;12:1387-93.

5) Oliverio MI, Coffman TM. *Angiotensin- receptors: New targets for antihypertensive therapy. Clin Cardiol* 1997 Jan;20:3-6.

6) Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, et al. *Pharmacological characterization of SR 47430, a new nonpeptide AT1 subtype angiotensin receptor antagonist. J Pharmacol Exp Ther* 1993;265:826-34.

7) Simon SR, Black HR, Moser M, Berland WE. *Cough and ACE inhibitors. Arch Intern Med* 1992;152:1698-700.

8) Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, et al. *An elective titration study of the comparative efficacy of irbesartan and losartan. Clin Ther* 1998;20:398-409.

9) Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, et al. *Comparison of the angiotensin receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press* 1998;7:31-7.

10) Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E, et al. *Comparative efficacy of two angiotensin receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens* 1998;11:445-53.

11) Robert Guthrie, et al. *Efficacy and tolerability of irbesartan, an angiotensin receptor antagonist, in primary hypertension. Clin Drug Invest* 1998 Mar;15:217-27.

12) Belz GG, Butzer R, Kober S, et al. *Time course and extent of angiotensin antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin dose response and radioligand receptor assay. Clin Pharmacol Ther* 1999 Oct;66:367-73.

13) Mazzolai L, Maillard M, Rossat J, et al. *Angiotensin receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension* 1999 Mar;33:850-5.

14) Kim NH, Jeong MH, Park WS, Kim SH, Kim JW, et al. *The Clinical Effect of Losartan (Cozaar®) on Hypertensive Patients. The Korean Circulation Journal* 1998;28: 1299-306.

15) Park DG, Lee MM, Chai IH, Rhee MY, Lee HJ, et al. *The Antihypertensive Efficacy, Safety, and Tolerability of Losartan Versus Fosinopril in Patients with Hypertension. The Korean Circulation Journal* 1998;28: 15-28.

16) Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, et al. *A randomized, double-blind comparison of the angiotensin receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Human Hypertens* 1998;12:203-8.